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Edited transcripts of research conferences 
sponsored by Organogenesis and the 
Washington University George M. O'Brien 
Center for Kidney Disease Research (P30 
DK079333) are published in Organogenesis. 
These conferences cover organogenesis in all 
multicellular organisms including research 
into tissue engineering, artificial organs and 
organ substitutes and are participated in 
by faculty at Washington University School 
of Medicine, St. Louis Missouri, USA.
Organogenesis Forum 
Organogenesis of Kidney and Endocrine Pancreas
The Window Opens
AbstRAct
Growing new organs in situ by implanting developing animal organ primordia 
(organogenesis) represents a novel solution to the problem of limited supply for human 
donor organs that offers advantages relative to transplanting embryonic stem (ES) cells or 
xenotransplantation of developed organs. Successful transplantation of organ primordia 
depends on obtaining them at defined windows during embryonic development within 
which the risk of teratogenicity is eliminated, growth potential is maximized, and 
immunogenicity is reduced. We and others have shown that renal primordia transplanted 
into the mesentery undergo differentiation and growth, become vascularized by blood 
vessels of host origin, exhibit excretory function and support life in otherwise anephric 
hosts. Renal primordia can be transplanted across isogeneic, allogeneic or xenogeneic 
barriers. Pancreatic primordia can be transplanted across the same barriers undergo 
growth, and differentiation of endocrine components only and secrete insulin in a 
physiological manner following mesenteric placement. Insulin-secreting cells originating 
from embryonic day (E) 28 (E28) pig pancreatic primordia transplanted into the 
mesentery of streptozotocin-diabetic (type 1) Lewis rats or ZDF diabetic (type 2) rats or 
STZ-diabetic rhesus macaques engraft without the need for host immune-suppression. 
Our findings in diabetic macaques represent the first steps in the opening of a window 
for a novel treatment of diabetes in humans.
intRoduction
Dr. Marc R. Hammerman: I am pleased to be able to deliver the inaugural 
Organogenesis Forum lecture. I am going to speak about organogenesis of the kidney and 
endocrine pancreas. The term ‘organogenesis’ has a number of definitions as reflected by 
the wide range of subject matter represented in Organogenesis, the journal. For purposes of 
this lecture, what I mean by ‘organogenesis’ is a novel technology for growing new organs 
in situ from transplanted embryonic organ primordia, in the development of which we 
and a number of other laboratories around the world are engaged.1
Previously, we have reviewed why the timing of primordia retrieval from embryos 
is important for organogenesis. In fact, there are ‘windows of opportunity’ for 
teratogenesis-free differentiation, vascularization and reduction of immunogenicity post-
transplantation.1 Recently, we have generated data that provide the basis for what, to 
our knowledge, is the first published report of organogenesis in non-human primates.2 
Since the use of non-human primates is a key intermediate step towards the employment 
of virtually any transplantation technology to replace kidney or endocrine pancreas in 
humans, our manuscript reflects the opening of a clinical window for organogenesis.2
oRgAnogenesis of Kidney
A shortage of human donor organs limits transplantation therapy for end-stage renal 
disease. We and others have suggested that theoretical strategies for kidney replacement 
therapies of the future include those listed in Figure 1: (1) the use of human ES cells; 
or (2) the use renal-specific precursors obtained from developed human kidneys (‘adult’ 
renal stem cells) to grow a new kidney; (3) therapeutic cloning; (4) xenotransplantation 
of developed animal kidneys to humans; (5) transplantation of differentiated kidney cells 
in lieu of whole kidneys (cell therapies); and (6) generation of new kidneys in situ from 
embryonic primordia (renal organogenesis).3 
The design of strategies to coax ES cells or ‘adult’ stem cells into generating a func-



















complex and renal function requires the precise integration in three 
dimensions of a large number of highly specialized cells vascularized 
at least in part from outside of the organ.3 ‘Close’ is not good enough 
to make a functioning kidney. Rather, renal ultrastructure must be 
perfect to permit glomerular filtration and tubular secretion and 
reabsorption. Because the kidney is so complicated I don’t think ES 
or ‘adult’ stem cells are good starting material for whole renal organ 
replacement. 
Organ formation in human embryos begins several weeks after 
implantation. At the present time, in the USA there is considerable 
controversy about the generation of human ES cells from fertilized 
ova. I don’t believe that it will ever be acceptable to clone and 
implant human embryos to the point of organ formation, effectively 
excluding this sort of therapeutic cloning as an organ-replacement 
therapy.3 Excluding ES and ‘adult’ stem cells and therapeutic 
cloning from my list, we are left with xenotransplantation of whole 
kidneys, renal cell therapies or organogenesis as theoretical means 
by which renal function can be recapitulated in lieu of human 
allotransplantation (Fig. 1). 
The use of pig kidneys instead of human organs makes sense 
because adult pigs and humans are the same size and weight and 
have almost identical renal function.4 Unfortunately, the use of pig 
kidneys in humans is not a viable option because of humoral rejec-
tion that occurs post-transplantation of vascularized pig organs into 
old-world primates. Humoral rejection is complement-mediated and 
results in large part from the binding of pre-formed circulating anti-
bodies directed against galactose-a-1,3-galactose, an antigen present 
on vascular endothelium of most mammals, but not old world 
primates and humans. 
The latter lack an enzyme a(1,3-galactosyl-transferase) required 
for galactose-a-1,3-galactose antigen formation.4-6 Humoral 
rejection of pig kidneys transplanted into non-human primates 
can be prevented by using kidneys from transgenic swine that 
express an enzyme on their vascular endothelium that deactivates 
complement, human decay accelerating factor5 or in which the 
gene for a-1,3-galactosyl-transferase is deleted.6 However, the 
intensity of cellular rejection of kidney transplants from such 
transgenic swine is such that the immune suppressive regimens 
required for engraftment in primate hosts result in complications 
that could never be tolerated in humans.5,6
Renal cell therapy of sorts has been carried out via implantation 
of sectioned7 or whole8 embryonic kidney primordia into renal 
parenchyma7 or beneath the kidney capsule.8 Under these conditions 
renal primordia differentiate into new nephrons in host kidneys. 
Unfortunately, the collecting systems of newly-developed donor 
nephrons and host kidneys do not connect, precluding excretion of 
urine and therefore clearance of filtered solutes. Also, transplantation 
into renal parenchyma or beneath the renal capsule is confining for 
newly-grown nephrons. As a result, obstruction occurs early during 
development and is manifest by formation of urine-containing cysts 
on the surface of host kidneys.8
In contrast to what occurs after implantation in renal paren-
chyma or beneath the renal capsule, renal primordia transplanted 
into a host rodent’s fold of mesentery undergo differentiation 
and growth in hosts (renal organogenesis) that is not confined 
anatomically.8-16 We8 and others11,12 have shown experimentally 
that growth is enhanced if one of the host's kidneys is removed 
at the time of implantation, and that timing of renal primordia 
retrieval is important [embryonic day (E)15 works best for trans-
planted rat primordia].1 If implanted into an adult rat with its 
ureteric bud attached, the renal primordium enlarges and becomes 
kidney-shaped within three weeks.8 The ureteric bud differenti-
ates into a ureter that can be anastomosed to the ureter of the host 
(ureteroureterostomy).8,9,13-16 Ureteroureterostomy turns out to be a 
key procedure for preserving the function of transplanted primordia. 
This is because the ureter must be freed from adhesions that often 
form as primordia develop in the mesentery. The adhesions obstruct 
the ureteric bud and prevent excretion of glomerular/tubular filtrate 
into the mesentery. As is the case for obstructed native kidneys 
during embryogenesis16 or for renal primordia implanted in renal 
parenchyma or beneath the renal capsule,7,8 the obstructed mesen-
teric transplant does not undergo normal renal differentiation, 
but rather atrophies and becomes fibrotic.16 Ureteroureterosomy 
preserves urine flow as the transplant differentiates. In our hands 
(rat-to-rat) it is not possible before 17 days post-transplantation 
because the ureter of the transplant is too friable. If ureterou- 
reterostomy is not performed by 21 days post-transplantation, 
obstruction results. Therefore this procedure must be performed 
between 17–21 days after transplantation of metanephroi from 
rat embryos into adult rats if optimal differentiation is to occur.16 
We have transplanted as many as four metanephroi at the same 
time (rat to rat) each of which undergoes growth and development 
in the mesentery. In our hands only one ureteroureterostomy is 
possible in the rat because of the small size of transplant and host 
ureters.16 However Marshall et al. are able to connect ureters from 
two transplants into the ureter of a host rat kidney.13
In contrast to transplanted developed kidneys that undergo acute 
rejection post transplantation into non-immunosuppressed hosts,8 
rat renal primordia differentiate into small, but ultrastructurally 
normal kidneys after allotransplantation in the mesentery. The new 
kidneys become vascularized via arteries that originate from the 
superior mesenteric artery of hosts and veins that originate from the 
host mesentery.14 Developed renal primordia produce urine that 
is excreted via the bladder following ureteroureterostomy between 
transplant and host. Levels of renal function in transplanted renal 
primordia [glomerular filtration rate (GFR)] can be determined by 
measuring inulin clearance in otherwise anephric rats. In our initial 
experiments GFRs were very low.8 However, incubation of renal 
primordia with growth factors prior to implantation increased GFRs 
more than 100-fold compared to those in rats with non growth 
factor-incubated renal primordia implanted concurrently. GFRs in 
growth factor treated renal primordia are about 6% of normal.14 
Others have reported even higher levels of GFR in rat-to-rat trans-
plants.9 Renal plasma flow can be measured in transplanted renal 
primordia by calculating P-aminohippurate (PAH) clearances. The 
ratio of GFR/PAH clearance (filtration fraction) is 0.6, comparable 
to filtration fractions measured in rats with reduced renal function. 
Urine flow rates in transplanted rats are about 12% of the inulin 
clearance (GFR) measured in growth factor-treated renal primordia. 
The UV/GFR of 0.12 demonstrates that developed primordia can 
concentrate urine.14
Figure 1. Organ replacement therapies of the future.


















Hemodialysis provides renal failure patients with GFRs that are 
about 10% of normal.3 Therefore, 6% of normal approximates a 
level of renal function that would be expected to preserve life. 
Indeed, life can be prolonged in otherwise anephric rat hosts by 
prior transplantation and ureteroureterostomy of a single renal 
primordium15 and survival can be extended if two primordia are 
connected to the host’s ureter.13 If the ureteroureterostomy is 
severed prior to removing all native renal mass from the host rat, 
survival is not prolonged.15 Therefore, metabolic functions of the 
transplant alone, are insufficient to preserve life in the absence of 
intact excretory function. 
There are four theoretical reasons why the use of developing 
renal primordia for transplantation might be advantageous relative 
to mature kidneys in terms of generating a reduced cellular rejection 
response and obviating humoral rejection. First, if developing renal 
primordia are obtained at sufficiently early stage, antigen-presenting 
cells (APCs) that mediate ‘direct’ host recognition of alloantigen 
or xenoantigen are absent.17-19 Second, donor antigens such as 
MHC Class I and II are not expressed on developing renal primordia 
to the extent they are expressed on mature renal tissue.20-22 Third, 
the immune response to transplanted fetal renal tissue is ameliorated 
relative to the response to adult tissue.23 Fourth, transplanted renal 
primordia are supplied by blood vessels of host origin.10,11, 24,25
We transplanted renal primordia from E15 Lewis rat embryos 
across a concordant xenogeneic barrier into the mesentery of 
10-week-old C57Bl/6J mice.24 In mice that receive immuno- 
suppression, but not in its absence, transplanted rat renal primordia 
undergo differentiation and growth in situ.24 
We next transplanted E28 pig renal primordia into C57Bl/6J 
mice26 or Lewis rats.25,27 The differentiation of E28 pig renal 
primordia is comparable to that of E15 rat renal primordia.25-27 
Pig renal primordia undergo growth and differentiation in 
immunosuppressed rodents, but not in the absence of host immune 
suppression. Figure 2 illustrates E28 pig renal primordia prior to 
transplantation (Fig. 2A and B) and seven weeks post-transplantation 
into immunosuppressed rat hosts (Fig. 2C–F). The maintenance 
immunosuppression regimen we used in rats.27 (Tacrolimus 2 mg/kg 
daily intramuscularly post-implantation) is one that could be 
tolerated in humans. 
Pig renal primordia transplanted in rats grow to a size larger than 
native rat kidneys in rat hosts.27 This suggests that the hypoplasia 
may be more characteristic of transplanted rat renal primordia than 
of pig renal primordia.16 Hypoplasia can result from excessive cell 
death in metanephric blastema.28,29 Rapidly-dividing blastema cells 
in renal primordia could be placed at risk during the time of relative 
hypoperfusion that occurs between dissection from donor embryos 
and re-vascularization in situ. It may be that pig renal primordia, 
cells in which divide more slowly over a longer gestation period, 
are at reduced risk for apoptosis relative to rat primordia during 
the time of relative hypoperfusion.16 Our finding of more complete 
differentiation (kidneys larger than native rat kidneys) following 
pig-to-rat xenotransplantation relative to rat-to-rat allotransplanta-
tion27 is consistent with this possibility. Experiments currently in 
progress will determine whether transplantation of pig kidneys in 
rats or larger animals will prolong the recipient’s life long-term. If so, 
embryonic pig kidneys may prove a suitable source for replacement 
of human renal function.
oRgAnogenesis of endocRine pAncReAs
Standard treatment for diabetes mellitus is insulin and diet. Such 
treatment is lifelong, painful and requires frequent monitoring of 
blood glucose. Tight control of glucose levels is impossible without 
inducing hypoglycemia. Even tight glucose control does not impact 
on long-term complications of diabetes.30
Transplantation therapy for type 1 diabetes consists of human 
pancreas or islet transplantation, the latter being an experimental 
therapy. Transplantation can restore normal glucose tolerance and 
prevent complications. However, it requires immune suppression, 
in effect trading one disease (diabetes) for another (immune 
suppression).30
There are insufficient human pancreas donor organs. Only about 
1,000 pancreas transplants are performed per year in the USA for its 
1.3 million type 1 diabetics. The shortage of donor organs effectively 
precludes transplantation for 20 million type 2 diabetics.31
In that pigs are plentiful and because porcine insulin works well 
in humans, the pig has been suggested as a pancreas organ donor 
for human diabetics.32-34 The severity of humoral rejection effec-
tively precludes their use as whole pancreas donors for non-human 
primates or humans. However, because they are vascularized by the 
host post-transplantation, isolated islets like other cell transplants are 
less susceptible to humoral rejection than pancreas transplants. Pig 
to human islet transplantation has been carried out without evidence 
for humoral-rejection.34 Unfortunately, even large numbers of 
transplanted porcine islets do not impact upon glucose control in 
human recipients.34 Recent experience with pig to non-human 
primate islet32 or neonatal islet33 transplantation shows that sustained 
insulin independence can be achieved, but only through the use of 
immunosuppressive agents that are not approved for human use or 
would result in an unacceptable level of morbidity in humans.
It has been known since the 1970s35,36 that glucose tolerance 
in alloxan—or streptozotocin (STZ)—diabetic rats (a model for 
type 1 diabetes) can be normalized after isotransplantation of 
Figure 2. Photomicrographs (a, c and D) and photographs (b, E and F) of 
pig renal primordia. (a and b) E28 primordia (s, stroma; ub, ureteric bud); 
(c–F) Pig renal primordia seven weeks post transplantation in a rat mesentery 
(c) Developed primordium in situ; (D) Primordium after removal from the 
mesentery (u, ureter) (E) cortex with a glomerulus (g) proximal tubule (pt) 
and distal tubule (dt) labeled. (F) Medulla with collecting ducts (cd) labeled. 
Magnifications are shown for (a and b) in (a); (c and D) in (D); for (E and 



















embryonic pancreatic primordia. Exocrine pancreas does not 
differentiate post-transplantation of pancreatic primordia obtained 
early during embryogenesis (E17).35-37 Thus, transplantation of 
pancreatic primordia from animal embryos represents an organ-
ogenesis solution for endocrine pancreas replacement without 
complications that accompany co-transplantation of exocrine 
pancreas such as digestion of host tissues from the action of 
pancreatic enzymes.30
In early experiments35,36 others transplanted embryonic pancreas 
beneath the renal capsule of hosts, a location from which insulin 
was released into the systemic venous circulation. It was shown 
subsequently that shunting venous flow from the systemic to 
portal systems post-transplantation improves diabetic control.37 This 
makes sense because normally, the pancreas secretes insulin directly 
into the portal vein from which it enters the liver directly.
We transplanted whole pancreatic primordia obtained from 
rat embryos just after organ formation begins (E12.5) into the 
mesentery of STZ -diabetic rats.38,39 On E12.5 the rat pancreas 
is undifferentiated and dorsal and ventral components remain 
separate.38 By four weeks post-transplantation of whole pancreatic 
primordia from E 12.5 Lewis rats into the mesentery of STZ-
diabetic Lewis rats, the tissue has undergone differentiation and 
islets of Langerhans can be delineated amidst stroma. There is no 
differentiation of exocrine tissue.38,39 Abnormal glucose tolerance 
in STZ diabetic rat hosts is normalized within two to four weeks 
post-isotransplantation of pancreatic primordia as is the pattern 
of abnormal weight gain characteristic of diabetic animals.38,39 
No host immunosuppression is required for isotransplantation of 
E12.5 rat embryonic pancreas. However engraftment following 
xenotransplantation from Lewis rat embryos to C57Bl/6J mice 
does require that hosts be immunosuppressed.38
Subsequently we showed that glucose tolerance can be normal-
ized in adult STZ -diabetic Lewis rats39,40 or in diabetic ZDF rats, 
a model for human type 2 diabetes41 following transplantation of 
pancreatic primordia from E28 pig embryos into the mesentery. 
Formerly-diabetic rats have porcine insulin, but no rat insulin 
detectable in circulation. Transcripts for porcine insulin are present 
in mesentery,39,40 liver, pancreas and mesenteric lymph nodes41 
post-transplantation. Light and electron microscopy show that 
individual pig beta cells are engrafted in the rat tissues. Consistent 
with the findings of Eloy et al who described normalization of 
glucose post-transplantation of E15, but not E18 embryonic chick 
pancreas into STZ-diabetic rats42 if pig pancreatic primordia are 
obtained within a developmental ‘window’ prior to E35 (E28 works 
best), they engraft in non-immunosuppressed immunocompetent 
diabetic rat hosts.39-41
To examine the utility for transplantation of pig pancreatic 
primordia in a non-human primate model, we implanted embryonic 
pancreas from E28 pig embryos into the mesentery of STZ-diabetic 
male rhesus macaques.2 Long-term engraftment of pig b-cells within 
liver, pancreas and mesenteric lymph nodes post-transplantation 
was demonstrated by electron microscopy, positive immune- 
histochemistry for insulin, and positive RT-PCR and in-situ hybrid-
ization for porcine proinsulin mRNA.2 Insulin requirements were 
reduced in one macaque followed over 22 months post-transplanta-
tion and porcine insulin detected in plasma using sequential affinity 
chromatography, HPLC and mass spectrometry. Of potential impor-
tance for application of this transplantation technology to treatment 
of diabetes in humans and confirmatory of our previous findings 
in Lewis and ZDF rats, no host immunosuppression is required.2 
Figure 3 shows photomicrographs originating from a mesenteric 
lymph node of a transplanted rhesus macaque. Sections in Figure 3A, 
C and E are stained with an anti-insulin antibody. Sections in 
Figure 3B, D and F are incubated with control serum. Sections of 
medullary sinus are delineated by arrows (Fig. 3A–D). Individual 
cells with b-cell morphology that stain positive (red) are delin-
eated by arrowheads (Fig. 3E). No positive-staining cells are 
found in sections treated with control serum (Fig. 3B, D and F). 
Cells with morphology similar to positive cells in Figure 3E are 
delineated in Figure 3F (arrowheads). No insulin-positive cells are 
present in mesenteric lymph nodes of non-transplanted rhesus 
macaques.2
Shown in Figure 4 are sections of mesenteric lymph node from 
a diabetic rhesus macaque that had been transplanted more than a 
year previously with E28 pig pancreatic primordia. In situ hybrid-
ization was performed using pig proinsulin antisense (Fig. 4A 
and C) or sense (Fig. 4B and E) probes. Cells within medullary 
sinuses stain (red) with the antisense, (Fig. 4A and C) but not the 
sense (Fig. 4B and D) probe. Intravenous glucose infusion was 
performed in the rhesus macaque at 600 days following the original 
transplantation. No rhesus macaque insulin (<0.1 ng/ml) was 
detected in circulation at any time. Analysis of circulating insulin 
at five minutes post-infusion revealed porcine insulin in circulation 
(Fig. 5A and B) Rhesus macaque insulin only was detected in plasma 
from a non-fasting non-diabetic non-transplanted rhesus macaque 
(Fig. 5C and D). Only porcine insulin was detected in plasma 
obtained from pigs.2
Transplantation of embryonic pancreas offers theoretical 
advantages relative to transplantation of either pluripotent embry-
onic stem (ES) cells, or of fully differentiated (adult) pancreas or 
islets from adults or neonatal animals. Specifically: (1) Unlike ES 
cells, pancreatic primordia obtained at the proper time during 
Figure 3. Photomicrographs of mesenteric lymph node from a STZ-diabetic 
rhesus macaque, 78 days post-transplantation of E28 pig pancreatic primor-
dia. (a, c and E) are stained with an anti-insulin antibody. (b, E and F) are 
stained using a control serum. Sections of medullary sinus are delineated by 
arrows (a–D). Individual cells with beta cell morphology are delineated by 
arrowheads (E and F). Scale bars 120 mm (a and b); 80 mm (c and D); and 
20 mm (E and F). Reproduced with permission (ref. 2).


















embryogenesis differentiate along defined organ-committed lines. 
There is no requirement to steer differentiation and no risk of 
teratoma formation;43 (2) Unlike the case for insulin-secreting 
cells derived from ES cells glucose-sensing and insulin-releasing 
functions are linked following in situ differentiation of transplanted 
pancreatic primordia;40 (3) The growth potential of cells within 
embryonic pancreas is enhanced relative to those in terminally-
differentiated adult pancreas or islets. It is possible to restore glucose 
tolerance in a diabetic rat by transplanting a single pancreatic 
primordium;44 (4) Only endocrine tissue differentiates following 
transplantation of pancreatic primordia obtained sufficiently early 
during embryogenesis obviating problems of host tissue digestion 
by exocrine pancreatic components 44 and (5) The cellular immune 
response to transplanted embryonic pancreas obtained early 
during embryogenesis is attenuated relative to that directed against 
organs obtained at later times.45
Our finding that pig pancreatic primordia engraft long-term 
in non-immunosuppressed STZ diabetic rhesus macaques opens 
a window for their potential for their use in human diabetics. 
If applicable in humans, successful organogenesis of endocrine 
pancreas (or kidney) could provide in essence, an unlimited supply 
of donor organs. This would result in a paradigm shift in how the 
world thinks about organ replacement (Fig. 6): 
(1) there will be no need to transport organs across long distances; 
 (2) transplantation can be done electively at a convenient time; 
(3) transplantation can be offered to high-risk individuals and 
 can be repeated as needed 
(4) transplantation can be offered to patients currently not 
 candidates including type 2 diabetics.41
Questions And AnsweRs
Dr. Melvin Blanchard, Associate Professor of Medicine, Washington 
University School of Medicine: Thank you, Marc, for an interesting 
talk. How far away are we from using pig pancreatic primordia in 
humans?
Dr. Hammerman: I think the observation that it is possible 
to transplant pig pancreatic primordia to non-human primates 
without an immunosuppression requirement is very important. 
The primordia engraft and secrete porcine insulin in the primate 
circulation. We can lower exogenous insulin requirements, but 
we have yet to normalize glucose tolerance in any transplanted 
primate. Until we do so it is premature to think about applying this 
technology in humans. Also, there is the issue of safety. We are 
about 2 ½ years out from our first pig-to-primate transplant.2 
That animal is doing well. However, we have a long way to go and 
many additional transplants to perform before we can be sure that 
what we are doing is safe for humans.
Dr. Bob Karsh (Professor of Medicine, Washington University School 
of Medicine): You have told us about organogenesis of the kidney 
and endocrine pancreas. Is organogenesis applicable to other 
organs such as the liver?
Dr. Hammerman: In the 1980s two different groups attempted 
allotransplantation of liver and kidney from E15 rat embryos into 
adult rats.17,18 The renal primordia engrafted in non-immunosup-
pressed hosts, but the livers were rejected. Co-transplantation of E15 
rat embryo liver and kidney resulted in rejection of both organs. 
The authors’ suggested that E15 rat livers, in contrast to kidneys, 
contain host-derived APCs that mediate direct antigen presentation 
resulting in rejection of liver or of liver and kidney transplanted 
at the same time.18 Hagihara et al. transplanted fragments of 
E18-19 fetal Wistar rat liver or E90 fetal swine liver into the 
omentum of non-immunosuppressed Wistar rats to which a lethal 
dose of D-galactosamine had been administered. The isografts 
formed nodules of hepatocytes at 72 hours post-transplantation, but 
the xenografts were necrotic by that time. Both isotransplantation 
and xenotransplantation improved survival.46
Eventov-Friedman et al. transplanted minced embryonic pig 
liver in the spleen or beneath the renal capsule of nonobese diabetic 
(NOD) severe combined immunodeficient (SCID) mice. 
Both hepatocytes and bile ducts differentiated post-transplanta-
tion and porcine albumin was detected in the circulation of host 
mice. Transplantation of liver primordia obtained from embryos 
younger than E28 resulted in teratoma formation beneath the renal 
capsule.43
Dr. Bharath M. Reddy (Instructor in Medicine, Washington 
University School of Medicine): It looks like you have had more 
success with pancreas organogenesis than with kidney organo-
genesis.
Dr. Hammerman: That’s one way to interpret our results. 
However, it’s probably too early to judge because it hard to know 
what the evenutal application for either technology will be. As 
an example of an alternative way to use the renal organogenesis 
technology, Yokoo et al. implanted labeled human mesenchymal 
stem cells (hMSC) into the nephrogenic site of E11.5 rat embryos 
before the metanephric kidneys had formed. Following 48 hours 
of whole embryo culture, the metanephric primordia had formed 
in vitro and contained hMSC. Metanephroi were dissected out 
and transplanted into the omentum of uninephrectomized rats. 
Transplants enlarged over two weeks in non-immunosuppressed 
rat hosts, became vascularized by host vessels and contained 
hMSC-derived cells that were morphologically identical to resident 
renal cells. These findings suggest that transplanted renal primordia 
might be useful as a scaffold to generate a ‘humanized’ kidney.11
Dr. Robert E. Schwartz (Resident in Medicine, Barnes-Jewish 
Hospital, Washington University School of Medicine): Have you seen 
any evidence for transmission of porcine endogenous retrovirus 
Figure 4. In situ hybridization was performed using pig proinsulin antisense 
(a and c) or sense probes (b and D) on sections of mesenteric lymph node 
originating from a STZ-diabetic rhesus macaque 407 days post-transplanta-
tion of E28 pig pancreatic primordia. Scale bars 80 mm (a and b) and 



















(PERV) from embryonic pig to non-human primates? Is this a 
concern?
Dr. Hammerman: It certainly is a concern. Several years ago 
Paradis et al. showed that despite persistent microchimerism 
(donor cells in human recipients of living pig tissue), PERV infec-
tion was not detected in human recipients.47 That is good news. 
Rood and Cooper have pointed out that transplantation of porcine 
islets into humans is being carried out all over the world. One hopes 
that mechanisms for informed consent and oversight are in place.48
Dr. Rashmi S. Mullur (Instructor in Medicine, Washington 
University School of Medicine): How do the pig pancreatic cells get 
into lymph nodes?
Dr. Hammerman: Good question. I can only speculate. In 
contrast to islet formation that occurs within stroma following 
transplantation of rat pancreatic primordia into diabetic rats or 
mice,38,39 individual endocrine cells engraft in tissues following 
transplantation of E28 pig pancreatic primordia into the mesentery 
of diabetic rats39-41 and also following transplantation of E28 pig 
pancreatic primordia into the mesentery of STZ-diabetic rhesus 
macaques.2 During normal pancreatic organogenesis, individual 
endocrine cells first migrate away from primitive ducts prior to 
coalescing into islets. Migration and coalescence are guided by a 
number of cell and tissue adhesion molecules. We speculated that 
the failure of individual pig endocrine cells to coalesce into islets 
post-transplantation of E28 pig pancreatic primordia into rats, may 
result from the absence of adhesion molecules in rat interstitium 
that are recognized by pig endocrine cells.40 Therefore following 
transplantation of pancreatic primordia from pig-to-rat, the 
endocrine cells cannot re-aggregate to form islets. In contrast, rat 
endocrine cells recognize rat or mouse adhesion molecules and 
islets are formed albeit in the absence of exocrine tissue.38
One explanation for our ability to transplant E28 pig pancreatic 
primordia without immunosuppression into rats or rhesus macaques 
may be that the absence of both exocrine tissue and islets results 
in a pattern of antigen expression that is not recognized as foreign 
by the host.38 An alternative explanation is host tolerance on the 
basis of chimerism as proposed by Abraham et al. to explain 
successful xenoengraftment of human pancreatic islet-derived 
progenitor cells in multiple tissues of non-immunosuppressed 
immunocompetent mice.49 Another is ‘T cell paralysis’50 on the 
basis host exposure to antigen in the form of cells that express class 
II major histocompatibility complex II (MHC II) in the absence of 
a co-stimulatory signal. Of course, such explanations would require 
that our pig beta cells express MHC II or the swine equivalent, 
swine leukocyte antigen (SLA) II. On first consideration, this might 
seem a bit far-fetched. However, under some circumstances pig 
b-cells do express SLA II.51,52
Neural cell adhesion molecule (NCAM) is one of the regulars 
for endocrine cell aggregation during islet development.53 Crnic 
et al. showed that loss of NCAM function causes the formation 
of lymph node metastasis in a transgenic model of pancreatic 
Figure 6. advantages of organogenesis.
Figure 5. chromatogram (a) and product ion mass spectrum (b) of porcine insulin (precursor ion [M+5H]5+ m/z 1156.3) extracted from 2 ml plasma 
obtained five minutes after IV glucose administration to a STZ-diabetic transplanted rhesus macaque. The retention time and diagnostic product ions derived 
from the five-fold charged precursor ion unambiguously identify porcine insulin. chromatogram (c) and product ion mass spectrum (D) of human/macaque 
insulin (precursor ion [M+5H]5+ m/z 1162.3) extracted from 1 ml of non-diabetic rhesus macaque plasma. The retention time and diagnostic product ions 
derived from the five-fold charged precursor ion unambiguously identify human/macaque insulin. Reproduced with permission (ref. 2).


















b-cell carcinogenesis. Metastases were facilitated by upregulated 
pancreatic lymphangiogenesis possibly induced by the disaggrega-
tion of endocrine cells.54 Possibly, the failure of endocrine cells to 
aggregate following transplantation of E28 pig pancreatic primordia 
in the mesentery of rats or rhesus macaques induces a comparable 
lymphagiogenesis that permits migration of beta cells to regional 
lymph nodes. A state of chimerism results and tolerance is induced 
on the basis of SLA II expression on beta cells in the absence of 
co-stimulatory molecules.2 It may be that diabetic patients will be 
the ultimate beneficiaries of this rather fortuitous series of events 
that might render hosts tolerant post-transplantation of E28 pig 
pancreatic primordia.
Dr. Karsh: You have told us about what happens after transplan-
tation of pancreas from E28 embryos. Have you tried transplanting 
pancreas from older embryos?
Dr. Hammerman: We have transplanted E28,2,40-41 E2939 or 
E3540 pig pancreatic primordia into non-immunosuppressed immu-
nocompetent rats39-41 or non-human primates.2 Our experience in 
rats is that E35 primordia are rejected. However, either E2840-41 
or E29 primordia39 engraft in rats and E28 work best in terms 
of regularly normalizing glucose tolerance in STZ-diabetic rats. 
Given the absence of an immunosuppression requirement for 
engraftment of E28 pig pancreatic primordia in rats, we went directly 
to testing their efficacy in diabetic non-human primates.2
Eventov Friedman et al. performed studies in which E21–E100 
pig pancreatic primordia were transplanted under the kidney 
capsule of immunodeficient NOD-SCID mice. They found optimal 
growth potential as reflected by the highest levels of porcine 
insulin in circulation from tissue harvested in the E42–E56 period. 
Differentiation of both endocrine and exocrine tissue was observed 
post-transplantation beneath the kidney capsule of the NOD-SCID 
mice.43 Subsequently Eventov-Friedman et al. showed that E42 
pig pancreatic primordia transplanted into NOD-SCID mice can 
restore normoglycemia in diabetic animals. Using assays for both 
direct and indirect T cell rejection responses to the xenogeneic tissue, 
they showed that E42 pig pancreatic tissue, in comparison to E56 
or later embryonic tissues, exhibits markedly reduced immuno-
genicity. Fully immunocompetent diabetic mice grafted with the 
E42 pig pancreatic tissue and treated with an immunosuppression 
protocol consisting of CTLA4-Ig and anti–CD40 ligand attained 
normal blood glucose levels following transplantation of E42 
primordia, eliminating the need for insulin.45
Dr. Karsh: Was there teratoma formation following transplanta-
tion of embryonic pancreas?
Dr. Hammerman: In contrast to what they reported after 
transplantation of embryonic pig liver obtained prior to E28 in 
NOD-SCID mice, Eventov-Friedman found no teratoma formation 
following transplantation of pig pancreas obtained from embryos at 
any age.43 We have never detected teratomas following transplanta-
tion of embryonic rat or pig pancreas. Our transplanted rats have a 
normal rat life span of about two years and outlive non-transplanted 
STZ-diabetic animals.
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